Chinese Clinical Expert Consensus on Immunotherapy for Hepatocellular Carcinoma(2021)

Title: Chinese Clinical Expert Consensus on Immunotherapy for Hepatocellular Carcinoma(2021)
Edition: Original
Classification: Experts consensus
Field: Treatment
Countries and regions: China
Guidelines users: Doctor
Evidence classification method: IA evidence derived from Meta-analysis results of multiple randomized controlled studies IB evidence derived from at least one well-designed randomized controlled study IIA evidence derived from at least one well-designed prospective non-randomized controlled study IIB evidence derived from at least one well-designed other type of intervention clinical study III evidence derived from a well-designed non-intervention study, such as descriptive studies, Correlation Studies and other IV evidence from Expert Committee reports or authoritative clinical experience of experts reported
Development unit: 中国医师协会肝癌专业委员会
Registration time: 2022-03-06
Registration number: IPGRP-2022CN108
Purpose of the guideline: To standard the immunotherapy for hepatocellular carcinoma(HCC)